about
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesisDeregulated AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma carcinogenesis and metastasis.The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.Expression of Molecular Differentiation Markers Does Not Correlate with Histological Differentiation Grade in Intrahepatic Cholangiocarcinoma.A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in CholangiocarcinomaAngiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathwayVerteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.Emerging role of Hippo signalling pathway in bladder cancer.Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial-mesenchymal transition.Gankyrin as a potential therapeutic target for cancer.(-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.Effect of YAP Inhibition on Human Leukemia HL-60 Cells.Positive regulatory interactions between YAP and Hedgehog signalling in skin homeostasis and BCC development in mouse skin in vivo.IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway.Upregulation of PSMD10 caused by the JMJD2A histone demethylase.Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury.YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells.Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview.Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.The Hippo signaling functions through the Notch signaling to regulate intrahepatic bile duct development in mammals.ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.YAP-associated chromosomal instability and cholangiocarcinoma in mice.Proteasome dysregulation in human cancer: implications for clinical therapies.STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.Expression of Hippo pathway genes and their clinical significance in colon adenocarcinoma.YAP/TAZ Activation as a Target for Treating Metastatic Cancer.YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD.Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.NUAK2 is a critical YAP target in liver cancer
P2860
Q26771988-7DF0481D-FDC3-46C2-90B6-00CEE6D09445Q33654365-ABE59876-D113-4CC0-B826-EC5CC839FD7EQ33815856-62528313-81FE-4997-A4E8-E91920AB15CFQ33827477-9B1F8682-2987-4168-A47C-2CE84D2A5FF6Q36046443-082A0C55-FDAD-43EC-B1FC-115CEA66B303Q36778814-E9C4FEAD-8CE4-4551-BFB0-F538D98E91E1Q37022185-A0A31790-8D26-449A-BD70-F1A9A40F9B90Q37233609-391C225A-02D7-474F-BC49-C89BAAF40071Q37701508-7D6AAD6F-2126-4FE7-B1ED-A9F37B6A401CQ37735656-4AF22CEF-6E82-40B8-899A-2660602B0A27Q38637679-08D3728F-2483-4A49-9F28-F3B2AA9FB6C9Q38698657-C6D4F77C-4CB4-4E2A-83A5-FFA08DE10FECQ38704712-477E2F40-7EE7-4946-925E-F104F74F272FQ39319386-2B8A5D82-24E1-44EA-A68E-341B64D52010Q39711667-FAD9FB36-BBCC-4156-A5E1-AFD10498D157Q41455333-10E66A92-8A72-478C-8AA2-2096DD115135Q41456020-C7CD1F3B-02D9-4A3B-9C1F-318072895BF0Q41472551-57FCB3B7-4144-408E-857A-EF624B5323A3Q41615123-67A5838A-BB26-4E16-A435-5334335B92D5Q42371988-98DEDB7B-0E48-4372-BF91-068C07502A8BQ43058864-E7856C3E-543F-4218-84E7-0B961962CA21Q47156470-C351C538-9BFB-4793-A78F-6207B0213C97Q47405466-28CE6F40-0958-4495-A6E2-9303A47A9495Q47603972-5AF3EA34-0444-4E9E-94EA-A3AE54593F10Q47661011-D96059DC-48CA-4532-8F66-ED5FEFFB2E3CQ47866385-216A7A86-683E-4E93-97CD-D1329AB09E3DQ49236278-BEED80E1-FD06-4865-9F62-D8A3402AF6B7Q49787756-90928AC9-A8B7-4BFE-9A3C-6F02706DF9B7Q50077966-24A6D5D9-1836-4F6F-9107-6812F2F22C0EQ52694945-F3CBFDCC-ACF9-4A9F-A33C-36B07E5AC990Q54940541-23FD8B52-055F-4782-BE56-D3E2A2A3B46AQ54977387-8D40ABF4-BA71-45EF-8E0C-165D29D332F2Q55397079-82CDBD11-2780-4657-B7B8-31524ABA4353Q55669129-19EE58CD-8B7C-4B27-A3B4-513ADA18CB3FQ59136619-5EC09136-0CEE-42EB-90E3-F40116E74073
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
YAP is a critical oncogene in human cholangiocarcinoma
@ast
YAP is a critical oncogene in human cholangiocarcinoma
@en
type
label
YAP is a critical oncogene in human cholangiocarcinoma
@ast
YAP is a critical oncogene in human cholangiocarcinoma
@en
prefLabel
YAP is a critical oncogene in human cholangiocarcinoma
@ast
YAP is a critical oncogene in human cholangiocarcinoma
@en
P2093
P2860
P356
P1433
P1476
YAP is a critical oncogene in human cholangiocarcinoma
@en
P2093
Dalong Yin
Huanlai Wang
Huawen Shi
Jiabei Wang
Lianxin Liu
Ruipeng Song
Shangha Pan
Tiemin Pei
P2860
P304
17206-17220
P356
10.18632/ONCOTARGET.4043
P407
P577
2015-07-01T00:00:00Z